4/A//SEC Filing
Title 19 Promis 4/A
Accession 0001104659-25-078637
CIK 0001374339other
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 4:18 PM ET
Size
12.8 KB
Accession
0001104659-25-078637
Insider Transaction Report
Form 4/AAmended
Title 19 Promis
Other
Transactions
- Exercise of In-Money
Tranche A Common Share Purchase Warrants
2025-07-25−119,800→ 345,316 total→ Common Shares (119,800 underlying) - Exercise of In-Money
Tranche C Common Share Purchase Warrants
2025-07-25−119,800→ 345,316 total→ Common Shares (119,800 underlying) - Exercise of In-Money
Tranche B Common Share Purchase Warrants
2025-07-25−119,800→ 345,316 total→ Common Shares (119,800 underlying)
Footnotes (4)
- [F1]On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
- [F2]This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.
- [F3]On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
- [F4]On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.
Documents
Issuer
ProMIS Neurosciences Inc.
CIK 0001374339
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0002005531
Filing Metadata
- Form type
- 4/A
- Filed
- Aug 13, 8:00 PM ET
- Accepted
- Aug 14, 4:18 PM ET
- Size
- 12.8 KB